Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody

20260 citationsJournal Articlehybrid Open Access

Authors

These results support further development of volrustomig as monotherapy and in combination regimens, with phase 3 trials ongoing.

Published in: Clinical Cancer Research

Field-Weighted Citation Impact: 0.00